| Value | ₹19.84 Cr |
|---|---|
| Execution period | 50 days |
BSE filing, NSE: GKSL. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹171.50
- Market cap
- ₹1,352 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 85.4×Sector 52.0×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Annual Report
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited has issued a notice for its 7th Annual General Meeting scheduled for September 28, 2026. The meeting will address financial statements, director appointments, and related party transactions.
- Value
- ₹1.78 Cr
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited filed a revised Annual Report for FY 2025-26. The document also includes the notice for its 7th Annual General Meeting.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr